JP2023531750A - ゴーシェ病を処置するためのアリモクロモル - Google Patents

ゴーシェ病を処置するためのアリモクロモル Download PDF

Info

Publication number
JP2023531750A
JP2023531750A JP2022580356A JP2022580356A JP2023531750A JP 2023531750 A JP2023531750 A JP 2023531750A JP 2022580356 A JP2022580356 A JP 2022580356A JP 2022580356 A JP2022580356 A JP 2022580356A JP 2023531750 A JP2023531750 A JP 2023531750A
Authority
JP
Japan
Prior art keywords
active pharmaceutical
pharmaceutical ingredient
use according
day
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022580356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531750A5 (enExample
Inventor
トマス キルケゴール イェンセン，
アンダース モルケベルグ ヒンスビー，
カトリン コルスター フォグトゥネセン，
リンダ インゲマン，
ダリ， クリスティーネ イ
Original Assignee
ケムファーム デンマーク アー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケムファーム デンマーク アー／エス filed Critical ケムファーム デンマーク アー／エス
Publication of JP2023531750A publication Critical patent/JP2023531750A/ja
Publication of JP2023531750A5 publication Critical patent/JP2023531750A5/ja
Priority to JP2026001474A priority Critical patent/JP7849574B2/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022580356A 2020-06-24 2021-06-24 ゴーシェ病を処置するためのアリモクロモル Withdrawn JP2023531750A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026001474A JP7849574B2 (ja) 2020-06-24 2026-01-07 ゴーシェ病を処置するためのアリモクロモル

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20182067.7 2020-06-24
EP20182067 2020-06-24
PCT/EP2021/067366 WO2021260120A1 (en) 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026001474A Division JP7849574B2 (ja) 2020-06-24 2026-01-07 ゴーシェ病を処置するためのアリモクロモル

Publications (2)

Publication Number Publication Date
JP2023531750A true JP2023531750A (ja) 2023-07-25
JP2023531750A5 JP2023531750A5 (enExample) 2024-07-02

Family

ID=71143584

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022580356A Withdrawn JP2023531750A (ja) 2020-06-24 2021-06-24 ゴーシェ病を処置するためのアリモクロモル
JP2026001474A Active JP7849574B2 (ja) 2020-06-24 2026-01-07 ゴーシェ病を処置するためのアリモクロモル

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026001474A Active JP7849574B2 (ja) 2020-06-24 2026-01-07 ゴーシェ病を処置するためのアリモクロモル

Country Status (14)

Country Link
US (1) US20230226036A1 (enExample)
EP (1) EP4171559B1 (enExample)
JP (2) JP2023531750A (enExample)
KR (1) KR20230035586A (enExample)
CN (1) CN116075305A (enExample)
AU (1) AU2021295437A1 (enExample)
BR (1) BR112022026396A2 (enExample)
CA (1) CA3183559A1 (enExample)
DK (1) DK4171559T3 (enExample)
ES (1) ES3056005T3 (enExample)
IL (1) IL299250A (enExample)
MX (1) MX2023000033A (enExample)
PT (1) PT4171559T (enExample)
WO (1) WO2021260120A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013125923A (ru) * 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019518725A (ja) * 2016-04-29 2019-07-04 オーファザイム エー／エス グルコセレブロシダーゼ関連障害を治療するためのアリモクロモル

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
EP2484371B1 (en) * 2008-06-26 2014-12-17 Orphazyme APS Use of Hsp70 as a regulator of enzymatic activity
NZ623910A (en) * 2009-07-28 2016-06-24 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019518725A (ja) * 2016-04-29 2019-07-04 オーファザイム エー／エス グルコセレブロシダーゼ関連障害を治療するためのアリモクロモル

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"STUDY OF ARIMOCLOMOL IN PATIENTS DIAGNOSED WITH GAUCHER DISEASE TYPE 1 OR 3", JPN6025032658, September 2019 (2019-09-01), ISSN: 0005660114 *
BIORXIV, JPN6025032662, 2018, pages 1 - 26, ISSN: 0005660115 *
EBIOMEDICINE, vol. 38, JPN6025032656, 2018, pages 144 - 155, ISSN: 0005660113 *
MOLECULAR GENETICS AND METABOLISM, vol. 123, no. 2, JPN6025032664, 2018, pages 79, ISSN: 0005660116 *

Also Published As

Publication number Publication date
EP4171559A1 (en) 2023-05-03
US20230226036A1 (en) 2023-07-20
MX2023000033A (es) 2023-04-10
WO2021260120A1 (en) 2021-12-30
DK4171559T3 (da) 2025-12-15
CN116075305A (zh) 2023-05-05
KR20230035586A (ko) 2023-03-14
EP4171559B1 (en) 2025-09-10
JP2026042936A (ja) 2026-03-11
ES3056005T3 (en) 2026-02-17
CA3183559A1 (en) 2021-12-30
PT4171559T (pt) 2025-12-16
IL299250A (en) 2023-02-01
BR112022026396A2 (pt) 2023-03-14
JP7849574B2 (ja) 2026-04-21
AU2021295437A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
US20250082651A1 (en) Ganaxolone for use in treating genetic epileptic disorders
EP3856478A1 (en) Formulations for treatment of dry eye disease
US12138245B2 (en) Methods for treating heterotopic ossification
JP7849574B2 (ja) ゴーシェ病を処置するためのアリモクロモル
KR20180054584A (ko) 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법
JP7757446B2 (ja) リソソーム蓄積障害に関する医薬組成物及び使用
AU2018337933A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
EP3659604A1 (en) Methods of providing weight loss therapy in patients with major depression
Han et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease
HK40090895A (en) Arimoclomol for treating gaucher disease
HK40090895B (en) Arimoclomol for treating gaucher disease
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
JP2025533042A (ja) 早期アルツハイマー病を処置するための方法
US20190247405A1 (en) Treatment of sma
EP4541372A1 (en) Drug therapy for obsessive-compulsive disorder targeting dopamine d1 signal in striatal striosomes
WO2025228863A1 (en) Dose regimen for a 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivative
WO2025162430A1 (zh) 一种药物联用及其在预防或治疗神经退行性疾病中的用途
HK40126638A (zh) 用於治疗焦虑及相关病症的ulotaront
CN116234579A (zh) 用于治疗神经退行性疾病的包含罗替戈汀和乙酰胆碱酯酶抑制剂的组合药物制剂
KAUR et al. A Comparative Trial to Evaluate Amitriptyline and Duloxetine in Painful Diabetic Neuropathy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251107

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20260121